Wellington Management Group
SRPT icon

Wellington Management Group’s Sarepta Therapeutics SRPT Stock Holding History

Wellington Management Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,530,455
Closed -$43.3M – 2101
2025
Q2 		$43.3M Sell
2,530,455
-116,164
-4% -$4.96M 0.01% 720
2025
Q1 		$169M Buy
2,646,619
+577,848
+28% +$60.8M 0.03% 387
2024
Q4 		$252M Sell
2,068,771
-657,842
-24% -$80.6M 0.05% 315
2024
Q3 		$341M Buy
2,726,613
+665,087
+32% +$91.9M 0.06% 276
2024
Q2 		$326M Sell
2,061,526
-1,184,272
-36% -$152M 0.06% 278
2024
Q1 		$420M Sell
3,245,798
-881,812
-21% -$108M 0.07% 249
2023
Q4 		$398M Buy
4,127,610
+217,810
+6% +$20.9M 0.07% 252
2023
Q3 		$474M Buy
3,909,800
+54,698
+1% +$6.18M 0.09% 215
2023
Q2 		$441M Buy
3,855,102
+921,490
+31% +$119M 0.08% 231
2023
Q1 		$404M Buy
2,933,612
+379,548
+15% +$49.2M 0.08% 245
2022
Q4 		$331M Sell
2,554,064
-4,805
-0.2% -$557K 0.07% 277
2022
Q3 		$283M Sell
2,558,869
-209,992
-8% -$21.2M 0.06% 285
2022
Q2 		$208M Buy
2,768,861
+88,383
+3% +$6.5M 0.04% 365
2022
Q1 		$209M Buy
2,680,478
+673,725
+34% +$51.6M 0.04% 405
2021
Q4 		$181M Buy
2,006,753
+607,291
+43% +$51.9M 0.03% 468
2021
Q3 		$129M Sell
1,399,462
-107,210
-7% -$8.26M 0.02% 551
2021
Q2 		$117M Sell
1,506,672
-11,002
-0.7% -$834K 0.02% 589
2021
Q1 		$113M Buy
1,517,674
+209,362
+16% +$19.3M 0.02% 577
2020
Q4 		$223M Buy
1,308,312
+26,375
+2% +$3.91M 0.04% 387
2020
Q3 		$180M Buy
1,281,937
+150,743
+13% +$22.9M 0.04% 394
2020
Q2 		$181M Buy
1,131,194
+185,782
+20% +$25.3M 0.04% 380
2020
Q1 		$92.5M Sell
945,412
-5,722
-0.6% -$654K 0.02% 482
2019
Q4 		$123M Buy
951,134
+946,151
+18,988% +$95.5M 0.03% 516
2019
Q3 		$376K Sell
4,983
-1,911
-28% -$226K ﹤0.01% 1916
2019
Q2 		$1.05M Buy
6,894
+717
+12% +$87.1K ﹤0.01% 1758
2019
Q1 		$737K Buy
6,177
+30
+0.5% +$3.86K ﹤0.01% 1828
2018
Q4 		$671K Buy
6,147
+2,377
+63% +$297K ﹤0.01% 1872
2018
Q3 		$609K Sell
3,770
-2,005
-35% -$274K ﹤0.01% 1988
2018
Q2 		$764K Sell
5,775
-10,206
-64% -$962K ﹤0.01% 1951
2018
Q1 		$1.18M Buy
+15,981
New +$1.07M ﹤0.01% 1862
2016
Q4 		– Sell
-13,526
Closed -$831K – 2263
2016
Q3 		$831K Buy
+13,526
New +$409K ﹤0.01% 1875
2014
Q2 		– Sell
-47,400
Closed -$1.14M – 2221
2014
Q1 		$1.14M Sell
47,400
-69,853
-60% -$1.78M ﹤0.01% 1808
2013
Q4 		$2.39M Sell
117,253
-218,490
-65% -$6.49M ﹤0.01% 1662
2013
Q3 		$15.9M Sell
335,743
-60,285
-15% -$2.32M 0.01% 1080
2013
Q2 		$15.1M Buy
+396,028
New +$14.2M ﹤0.01% 1063

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Wellington Management Group's SRPT Position: Q3 2025 in Review

Wellington Management Group sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 2,530,455 shares — an estimated $43.3M sold.

Wellington Management Group first reported a position in SRPT in Q2 2013 and held it in 35 quarters. The position peaked at $474M in Q3 2023. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Wellington Management Group reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wellington Management Group sold 2,530,455 Sarepta Therapeutics shares in Q3 2025, an estimated $43.3M.
  • Wellington Management Group first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 35 quarters.
  • Wellington Management Group's Sarepta Therapeutics position peaked at $474M in Q3 2023.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Wellington Management Group's 13F filing for Q3 2025, filed 14 Nov 2025.